Trials / Completed
CompletedNCT00441116
A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia
An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 153 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this Phase III study is to compare the efficacy, safety and tolerability of dutasteride (0.5mg) with placebo for 6 months, in Korean male subjects with androgenetic alopecia in the vertex region, types IIIv, IV and V according to the modified Norwood-Hamilton Classification.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dutasteride 0.5mg oral tablets | Dutasteride |
Timeline
- Start date
- 2006-12-15
- Primary completion
- 2008-01-21
- Completion
- 2008-01-21
- First posted
- 2007-02-28
- Last updated
- 2018-08-16
- Results posted
- 2009-04-22
Source: ClinicalTrials.gov record NCT00441116. Inclusion in this directory is not an endorsement.